This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fefer, A. Articles by Glynn, J. P. Search for Related Content PubMed PubMed Citation Articles by Fefer, A. Articles by Glynn, J. P.

Studies on the Growth and Regression of a Transplantable Moloney Sarcoma

HEW, NIH, Bethesda, Maryland 20014, and Microbiological Associates, Inc., Bethesda, Maryland

X-irradiated (400 R) CBF (BALB/c x C57BL/6 ) F₁ mice inoculated with BALB/c Moloney sarcoma cells developed more tumors and exhibited fewer tumor regressions than normal CBF controls. Most of the latter and only one of the former produced detectable fluorescent antibody as tested against BALB/c Moloney lymphoma cells. BALB/c Moloney sarcoma cells incubated with spleen cells from C57BL/6 mice whose primary Moloney-sarcoma-virus-induced tumors had regressed did not grow in X-irradiated CBF hosts. Mice inoculated with Moloney sarcoma cells after incubation with immune serum developed as many tumors as mice inoculated with Moloney sarcoma cells incubated with normal C57BL/6 serum. However, the latency period to tumor development was longer in the former. Absorption studies showed that the tumors which developed lacked somatic isoantigens of the C57BL/6 genotype, in contrast to primary CBF Moloney sarcoma cells. The data presented are consistent with the hypothesis that tumor rejection is largely mediated by immune lymphoid cells.

¹ U. S. Public Health Corps.

² Drug Evaluation Branch, National Cancer Institute, NIH.

³ Microbiological Associates, Inc., Bethesda, Maryland.

Received 4/24/67. Accepted 7/13/67.